SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-101595
Filing Date
2023-09-18
Accepted
2023-09-18 16:17:52
Documents
13
Period of Report
2023-09-15
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2326323d1_8k.htm   iXBRL 8-K 27850
2 EXHIBIT 3.1 tm2326323d1_ex3-1.htm EX-3.1 4511
  Complete submission text file 0001104659-23-101595.txt   208042

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nbse-20230915.xsd EX-101.SCH 3048
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbse-20230915_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbse-20230915_pre.xml EX-101.PRE 22381
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2326323d1_8k_htm.xml XML 3327
Mailing Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219
Business Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219 412-763-3350
NeuBase Therapeutics, Inc. (Filer) CIK: 0001173281 (see all company filings)

IRS No.: 465622433 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35963 | Film No.: 231261400
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences